Últimas noticias sobre Lifecore Biomedical (NASDAQ:LFCR) Bolsa

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Lifecore Biomedical Inc

Wells Fargo analyst Mike Mayo maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Overweight and raises the price target from $20 to $22.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on KeyCorp, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Emeren Group, Maintains $7 Price Target

Wells Fargo analyst Mike Mayo maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Overweight and raises the price target from $240 to $270.

Wells Fargo Maintains Overweight on JPMorgan Chase, Raises Price Target to $270

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) saw a surge in its stock price during Friday&#8217;s premarket trading, driven by positive news surrounding the company&#8217;s growing production capacity and <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">international expansion efforts</a>.
At the 2024 Guangzhou Auto Show on November 14, Alan Ai, President of NIO&#8217;s sub-brand Onvo, shared updates about the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/41912881/whats-going-on-with-nio-stock-today-9" rel="noreferrer noopener">Onvo L60 electric vehicle.</a> According to Ai, more than 7,000 units of the L60 have been delivered to customers, signaling strong demand for the model, <a target="_blank" href="https://cnevpost.com/2024/11/15/nio-onvo-deliveries-exceeded-7000/" rel="noreferrer noopener">reported</a> CnEV Post.
Recent <a target="_blank" href="https://cnevpost.com/2024/11/12/nio-onvo-l60-wait-time-reduced/" rel="noreferrer noopener">reports</a> indicate that NIO has managed to shorten the delivery timeline for the Onvo L60. Customers in China can now expect their vehicles to arrive in just 10 to 14 weeks, down from the previous 12 to 16 weeks. This reduction in wait times suggests that NIO has successfully ramped up its production capacity to meet the growing demand for its vehicles. The change was confirmed through updates on the Onvo app, further reinforcing the idea that the company is scaling its operations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math" rel="noreferrer noopener">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a>
Ai also outlined ambitious targets for future deliveries, stating that Onvo aims to exceed 10,000 units per month in December and reach more than 20,000 units per month by March 2025. The Onvo L60 has already seen strong order volumes, far outpacing the demand for other models launched at the same time. As a result, production orders for the first quarter of 2025 are already in place, further demonstrating the model&#8217;s popularity.
In addition to its domestic growth, NIO is expanding its footprint internationally. The company revealed plans to enter the Azerbaijani automotive market, a move that reflects its broader strategy of global expansion, CnEV Post <a target="_blank" href="https://cnevpost.com/2024/11/15/nio-to-enter-azerbaijan/" rel="noreferrer noopener">reports</a>. Qin Lihong, NIO&#8217;s co-founder and president, shared the news in a WeChat video, confirming that he is currently visiting Baku, the capital of Azerbaijan, as part of the company&#8217;s efforts to grow its presence beyond China.
With strong sales figures, ramped-up production capabilities, and an expanding international footprint, NIO appears to be well-positioned for continued growth in the global electric vehicle market.
Price Action: Nio shares traded higher by 1.35% at $4.49 premarket at the last check Friday.
Photo by Sundry Photography on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a></li>
</ul>

Equities

Markets

Movers

Media

General

What's Going On With NIO Stock Today?

Northland Capital Markets analyst Michael Latimore maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and lowers the price target from $275 to $250.

NICE

Northland Capital Markets Maintains Outperform on NICE, Lowers Price Target to $250

Northland Capital Markets analyst Mike Grondahl maintains Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) with a Outperform and raises the price target from $8.25 to $8.75.

LGCY

Northland Capital Markets Maintains Outperform on Legacy Education, Raises Price Target to $8.75

WIIM

Nu Holdings shares are trading lower. Berkshire Hathaway in a 13F filing disclosed that it reduced its stake in Nu Holdings by 19%.

Wells Fargo analyst Whit Mayo maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Overweight and raises the price target from $52 to $54.

FITB

Wells Fargo Maintains Overweight on Fifth Third Bancorp, Raises Price Target to $54

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)&nbsp;stock is trading higher Friday after the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004020/alibaba-group-announces-september-quarter-2024-results" rel="noreferrer noopener">fiscal second-quarter&nbsp;print</a>.
The Jack Ma co-founded e-commerce giant reported fiscal second-quarter 2024 revenue growth of 5% year-on-year to $33.70 billion, beating the analyst consensus estimate of $33.47 billion. Adjusted earnings per ADS of $2.15 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.26</a>.&nbsp;
Adjusted net income declined 9% Y/Y to $5.20 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41973754/bilibilis-q3-earnings-revenue-surges-26-record-user-growth-margins-improve-as-games-lead-the-way" rel="noreferrer noopener">Bilibili's Q3 Earnings: Revenue Surges As Games Lead the Way, Stock Buyback And More</a>
Segments: Taobao and Tmall Group revenue grew by 1% year over year to $14.11 billion. Alibaba International Digital Commerce Group revenue increased by 29% year over year to $4.51 billion, driven by the growth of cross-border businesses, in particular AliExpress's&nbsp;Choice&nbsp;business.
Local Services Group revenue grew by 14% year over year to $2.53 billion, driven by the order growth of both Amap and Ele.me and revenue growth from marketing services.&nbsp;
Cainiao Smart Logistics Network Limited's revenue increased 8% year over year to $3.51 billion, driven by an increase in revenue from cross-border fulfillment solutions.&nbsp;
Cloud Intelligence Group revenue grew by 7% Y/Y to $4.22 billion. Digital Media and Entertainment Group fell by 1% Y/Y to $811 million. All other revenue grew by 9% Y/Y at $7.44 billion.
In the Taobao and Tmall Group, customer management revenue grew 2% year over year due to the growth in online GMV.
Revenue from China's commerce retail business remained firm year over year at $13.25 billion, while direct sales and other revenue declined by 5% year over year to $3.23 billion, primarily due to the decrease in appliance sales.
Revenue from China's commerce wholesale business grew by 18% year over year to $853 million due to the increase in revenue from value-added services provided to paying members.
Alibaba International Digital Commerce Group:&nbsp;International commerce retail business revenue grew by 35% Y/Y to $3.65 billion, primarily driven by the increase in revenue contributed by AliExpress'&nbsp;Choice&nbsp;and Trendyol.&nbsp;
International commerce wholesale business revenue grew by 9% Y/Y to $863 million.
Cloud Intelligence Group:&nbsp;Overall revenue, excluding Alibaba-consolidated subsidiaries, increased by 7% Y/Y, which was mainly driven by the double-digit revenue growth of public cloud products, including AI-related products.
As of September 30, 2024, Alibaba held $79 billion in cash and equivalents. It generated an operating cash flow of $4.48 billion, down 38% year over year.
During the quarter, it generated a free cash flow of $1.96 billion, down 70% year over year due to investments in Alibaba Cloud infrastructure, refunds to Tmall merchants and other working capital changes related to factors including the scale-down of certain direct sales businesses.
Alibaba Group CEO Eddie Wu noted strong performance in the Cloud segment, with public cloud product revenue seeing double-digit growth and AI-related offerings delivering triple-digit gains. He expressed increased confidence in Alibaba's core businesses and plans to continue investing for sustained long-term growth.
Wu also pointed out improved operating efficiency across other segments, with many achieving higher profitability or narrowing losses.
Alibaba CFO Toby Xu attributed the quarter's revenue growth to better monetization of the Taobao and Tmall platforms, including increased adoption of GMV-based service fees and the marketing tool Quanzhantui.
Xu stated that Alibaba repurchased $4.1 billion worth of shares during the quarter, reducing the total shares outstanding by 2.1% since the end of June, which contributed to increased earnings per share for shareholders.
Price Action:&nbsp;BABA shares traded higher by 3.80% at $94.02 premarket at&nbsp;the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41970826/jd-com-q3-earnings-revenue-beats-forecast-amid-consumer-rebound-highlights-supply-chain-strength-eyes-margin-growth" target="_blank" rel="noreferrer noopener">JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth</a></li>
</ul>
Photo Via Shutterstock

Earnings

Emerging Markets

Tech

BABA

Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments

Albany International Corp. Says Unit Heimbach Switzerland Ag Will Initiate Consultations With Employee Representatives Regarding A Proposal To Discontinue Manufacturing Operations In Olten, Switzerland, And To Transfer Production To Other Heimbach Manufacturing Facilities

Wells Fargo analyst Mike Mayo maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Overweight and raises the price target from $85 to $95.

Wells Fargo Maintains Overweight on Citigroup, Raises Price Target to $95

BSFC

Blue Star Foods shares are trading higher after the company announced it signed a vendor agreement with Lowtide.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) from $36 to $41. Goldman Sachs analyst Andrea Tan maintained a Neutral rating. Tarsus Pharmaceuticals shares closed at $46.65 on Thursday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from $115 to $131. Deutsche Bank analyst Bryan Kraft maintained a Buy rating. Disney shares closed at $109.12 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) price target from $125 to $145. Needham analyst Mayank Tandon maintained a Buy rating. Agilysys shares settled at $120.84 on Wednesday. <a href="https://www.benzinga.com/quote/AGYS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) price target from $240 to $225. Needham analyst Charles Shi maintained a Buy rating. Applied Materials shares closed at $186.00 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock.</a></li>
<li></li>
<li>Piper Sandler boosted Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $565 to $575. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Mastercard shares closed at $520.40 on Thursday.  <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) price target from $55 to $60. Benchmark analyst Cody Acree maintained a Buy rating. Tower Semiconductor shares closed at $46.30 on Thursday. See how other analysts view this stock.</li>
<li>Morgan Stanley cut the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $23 to $9. Morgan Stanley analyst Andrew Percoco downgraded the stock from Equal-Weight to Underweight. SolarEdge shares settled at $12.83 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) price target from $294 to $300. Baird analyst Brian Skorney maintained an Outperform rating. Biogen shares closed at $164.89 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from $385 to $425. Baird analyst Shrenik Kothari maintained an Outperform rating. Palo Alto shares closed at $394.39 on Thursday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) price target from $32 to $30. HC Wainwright &amp; Co. analyst Emily Bodnar maintained a Buy rating. Genelux shares closed at $2.94 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png" alt="" class="wp-image-650089" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170.png 1256w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

AGYS

AMAT

BIIB

GNLX

PANW

SEDG

TARS

TSEM

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Roth MKM analyst Darren Aftahi initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy rating and announces Price Target of $25.5.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Roth MKM Initiates Coverage On Core Scientific with Buy Rating, Announces Price Target of $25.5

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Shares of US-listed Chinese e-commerce companies are trading higher amid possible sympathy with Alibaba Group Holding after the company reported Q2 financial results.

Blue Star Foods Inks Vendor Agreement With Lowtide, Under Wicked Tuna Seafood & Toby Keith's Premium Brands

Wells Fargo analyst Whit Mayo maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Overweight and raises the price target from $52 to $56.

Wells Fargo Maintains Overweight on Bank of America, Raises Price Target to $56

Truist Securities analyst Ki Bin Kim maintains Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) with a Buy and raises the price target from $28 to $31.

Truist Securities Maintains Buy on Brixmor Property Group, Raises Price Target to $31

Wedbush analyst Nick Setyan reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.

Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) with a Overweight and lowers the price target from $9 to $4.

OMGA

Piper Sandler Maintains Overweight on Omega Therapeutics, Lowers Price Target to $4

Lifecore Biomedical raises $24.3M through private placement

Lifecore Biomedical ( ($LFCR) ) has shared an update. Lifecore Biomedical, Inc. successfully closed a private placement of 5,928,775 shares of comm...

Lifecore Biomedical Raises $24.3M, Expands Capacity and Clientele

Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript

Barrington analyst Michael Petusky has maintained their neutral stance on LFCR stock, giving a Hold rating on October 4. Michael Petusky's rating i...

Lifecore Biomedical: A Cautious Hold Amid Modest Growth and Financial Challenges

Lifecore Biomedical GAAP EPS of -$0.53, revenue of $24.7M

Lifecore (LFCR) Biomedical announced that it has appointed Thomas Guldager as vice president, operations. An experienced pharmaceutical industry pr...

Lifecore appoints Guldager as vice president, operations

Lifecore (LFCR) Biomedical announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will ...

Lifecore to host virtual investor day on November 21

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares closed yesterd...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Greenhaven Road Capital Q3 2024 Investor Letter

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

CLBT

CTLT

HGTY

LFCR

SBUX

Legal

Press Releases

LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Biotech

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Financing

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Comments

Lifecore Biomedical

Noticias

Últimas noticias sobre Lifecore Biomedical (NASDAQ:LFCR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL